Research Article

Auditory Neuropathy Spectrum Disorder (ANSD)—Clinical Characteristics and Pathogenic Variant Analysis of Three Nonsyndromic Deafness Families

Rongqun Zhai,1 Haifeng Feng,1 Qingli Li,2 Wei Lu,1 Danhua Liu,3 Yongan Tian,4,5 Huanfei Liu,6 Ruijun Li,6 Bin Zuo,1 Wenxue Tang,3,5,6 Hongen Xu5,6 and Bei Chen1

1Department of Otorhinolaryngology, Head and Neck Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
2Department of Pediatrics, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
3Center for Applied Precision Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China
4BGI College, Zhengzhou University, Zhengzhou 450052, China
5Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450052, China
6Precision Medicine Center, Academy of Medical Science, Zhengzhou University, Zhengzhou 450052, China

Correspondence should be addressed to Hongen Xu; hongen_xu@zzu.edu.cn and Bei Chen; chenbei815@163.com

Received 1 October 2020; Revised 23 November 2020; Accepted 12 December 2020; Published 22 December 2020

Objective. To analyze the phenotypic features and pathogenic variants of three unrelated families presenting with nonsyndromic auditory neuropathy spectrum disorder (ANSD).

Methods. Three recruited families that were affected by congenital deafness were clinically evaluated, including a detailed family history and audiological and radiological examination. The peripheral blood of all patients and their parents was collected for DNA extraction, and then, the exonic and flanking regions were enriched and sequenced using targeted capture and high-throughput sequencing technology. Bioinformatics analyses and the Sanger sequencing were carried out to screen and validate candidate pathogenic variants. The pathogenicity of candidate variants was evaluated by an approach that was based on the standards and guidelines for interpreting genetic variants as proposed by the American College of Medical Genetics and Genomics (ACMG).

Results. Four patients in three families were diagnosed as nonsyndromic ANSD, and all exhibited OTOF gene mutations. Among them, two individuals in family 1 (i.e., fam 1-II-2 and fam 1-II-3) carried homozygous variants c.[2688del];[2688del] (NM_194248.3). Two individuals from family 2 (fam 2-II-1) and family 3 (fam 3-II-4) carried compound heterozygous variants c.[4960G>A];[1469C>G] and c.[2675A>G];[2977_2978del], respectively.

Conclusions. Three unrelated pedigrees with ANSD were caused by pathogenic variants in the OTOF gene. Five mutations were found and included c.2688del, c.2675A>G, c.2977_2978del, c.4960G>A, and c.1469C>G, of which the first two are novel and expanded mutational spectrum of the OTOF gene, thus having important implications for genetic counseling of the family.

1. Introduction

Hereditary hearing impairment is a frequently observed sensory and disabling disease, which causes incredibly negative consequences to patients—both psychologically and physiologically. Hereditary hearing impairment can be divided into two distinct categories that include the syndromic type, with abnormalities found in other parts of the body, and the nonsyndromic type. Nonsyndromic hearing loss (NSHL) accounts for 70% of the overall incidence and is an exceedingly heterogeneous disease [1]. NSHL is mainly transmitted as autosomal recessive, autosomal...
dominant, or X-linked inheritance patterns. Hitherto, up to 100 genes have been implicated in hereditary nonsyndromic deafness (https://hereditaryhearingloss.org/).

Auditory neuropathy (AN), which is a particular type of auditory dysfunction with impaired speech comprehension, was first coined and nominated by Sttar in 1996 [2], which is also referred to as an auditory neuropathy spectrum disorder (ANSD). ANSD is subdivided into “postsynaptic” or “presynaptic” types, depending on whether the auditory nerve is involved or the inner hair cells (IHC), and synaptic lesions are involved [3]. ANSD can cause varying degrees of hearing impairment. Diagnosis can be made on the presentation of severe anomalies or absence in the auditory brainstem response (ABR), and the presence of otoacoustic emissions (OAEs) and cochlear microphonics (CM), as well as an attenuation in speech perception that is out of proportion to the pure-tone threshold [2, 4]. We have arrived at a plausible evaluation in speech perception that is out of proportion to the auditory neuropathy spectrum disorder (ANSD). ANSD is subdivided into “postsynaptic” or “presynaptic” types, depending on whether the auditory nerve is involved or the inner hair cells (IHC), and synaptic lesions are involved [3]. ANSD can cause varying degrees of hearing impairment. Diagnosis can be made on the presentation of severe anomalies or absence in the auditory brainstem response (ABR), and the presence of otoacoustic emissions (OAEs) and cochlear microphonics (CM), as well as an attenuation in speech perception that is out of proportion to the pure-tone threshold [2, 4]. We have arrived at a plausible conjecture that the auditory pathway up to and including the outer hair cells (OHCs) in ANSD patients is intact and that the primary lesions might represent a malfunction or defect of the IHCs, the auditory synapses, or the auditory nerve itself [2]. These lesions can affect the processing ability of rapid acoustic signals so that the sound signals cannot be transmitted synchronously from the inner ear to the auditory cortex. The etiology of ANSD is complex, and various etiologies underlying ANSD, which include OTOF, DFNB59, and DIAPH3 genes, have been frequently revealed [7]. To date, nearly 200 variants of the OTOF gene have been deposited in the Human Gene Mutation Database (HGMD), which is the primary causative gene in infants affected by ANSD.

The OTOF gene is located at the DFNB9 locus and was the first identified causative gene associated with nonsyndromic ANSD by Yasunage et al. in 1999 [8]. The OTOF gene is located in 2p23.1 and contains 48 exons that encode the otoferlin protein [9]. The coding product has multiple isoforms with unequal lengths due to alternative translation start sites and splicing sequences. Among them, a long isoform with 1997 amino acid residues contains a C-terminal transmembrane domain (TMD) that is involved in docking to the cytoplasmic membrane and six C2 domains (C2A-C2F) that permit binding to $Ca^{2+}$ and $Ca^{2+}$-dependent related proteins [10]. Studies have shown that the otoferlin protein plays an essential role in the exocytosis and replenishment of neurotransmitters in IHC synaptic vesicles and does so by triggering synaptic membrane fusion in a $Ca^{2+}$-activated manner [10–13]. It has also been demonstrated that the otoferlin protein is invariably expressed and concentrated in the basolateral region of the IHCs in the mature mouse cochlea and is an essential component of the presynaptic structure of IHCs [14]. Thus, researchers speculated that mutations in OTOF might affect the structure or function of the otoferlin protein at the IHC ribbon synapse, leading to differential magnitudes in hearing loss. Patients with mutations in OTOF exhibit presynaptic nonsyndromic AN; moreover, cochlear implantation (CI) can achieve a favorable outcome [15–17].

Herein, we examined and described in some detail patients affected by ANSD; following which, we performed whole-exome and the Sanger sequencing to unravel possible etiologies in these sporadic families with ANSD. Consequently, mutations in the OTOF gene were identified as being disease-causing in these patients.

2. Materials and Methods

2.1. Family Description and Clinical Examination. In this study, families 1-3, which comprised three unrelated Chinese pedigrees, including four affected patients with nonsyndromic hearing loss (NSHL) and their phenotypically healthy parents, were recruited. Four affected offspring who presented with prelingual and bilateral sensorineural deafness were diagnosed by head and neck surgery at the First Affiliated Hospital of Zhengzhou University. Detailed family and medical histories were recorded. Subsequently, all patients underwent speech audiometry, electrocochleography, cochlear microphonics (CM), otoacoustic emission (OAE), auditory brainstem response (ABR), and multifrequency steady-state auditory evoked response (ASSR). In addition, other audiological examinations were performed to evaluate audiological characteristics. Temporal bone CT and magnetic resonance imaging (MRI) were also carried out to exclude inner ear dysplasia and intracranial lesions. Peripheral blood was taken after obtaining signed informed consent from all participants. The experimental protocol of this study was authorized by the local Medical Ethics Committee of the First Affiliated Hospital of Zhengzhou University and was compliant with the Helsinki Declaration of the World Medical Association.

2.2. Whole-Exome Sequencing. All four patients (3 probands and an affected sib) in our study were subjected to a preliminary screening using whole-exome sequencing. DNA extraction, fragmentation, library construction, targeted enrichment, and sequencing were performed as described previously [18].

2.3. Bioinformatics Analysis and Variation Interpretation. Sequencing fragments were processed using Trimmomatic [19] to eliminate adapters and inferior reads. After quality control, the clean reads were aligned to the human reference genome (version number hg19) using the Burrows-Wheeler Aligner [20]. The GATK HaplotypeCaller software [21] (version 4.1.2) was also applied to detect single-base variations and short insertions or deletions. Variant annotation, filtering, and interpretation were carried out as described previously [18].

2.4. Sanger Sequencing. The candidate mutations were validated by PCR amplification and the Sanger sequencing. The primers described below (Table 1) were designed and synthesized with the aim of detecting variations in probands and their families. PCR amplification was carried out using a 2x Taq Master Mix kit with a system of 25 μL. The amplified products were identified by 2.2% agarose gel electrophoresis to determine the fragment size and then purified with a DNA product purification kit. Purified PCR products were
sequenced using the SeqStudio Genetic Analyzer (Applied Biosystems/Life Technologies, Carlsbad, CA, USA).

3. Results

3.1. Clinical Features. The comprehensive family and medical histories revealed that all families had no similar cases or exposure to risk factors, such as neonatal jaundice, and infections. Three pedigrees are plotted in Figure 1. The results of electrocochleography showed that four individuals (i.e., 1-II-2, 1-II-3, 2-II-1, and 3-II-4) displayed intact bilateral tympanic membranes, and there was evidence of an apparent bilateral hydrotympanum in the proband 1-II-2. ABRs were indistinguishable or absent in all patients, and their ASSR examination also showed severe-to-profound sensorineural deafness in both ears. Normal bilateral OAEs were detected in proband 1-II-2 and his two-year-old sister all carried the c.2688del variant in a homozygous state. They inherited the damaging mutations from both their heterozygous healthy parents. The c.2688del variant is a frameshift mutation causing a loss of function (LOF) of the OTOF gene and LOF is a known mechanism of disease for this gene (PM2). This novel mutation was absent in 1000 Genomes, ExAC, and gnomAD (PM2). Multiple lines of computational evidence supported a deleterious effect of G nucleotide deletion at position 2688 on the OTOF gene (PP3). The clinical manifestations of the patients were consistent with the phenotype of the disease caused by the OTOF gene (PP4). Thus, based on ACMG standards and guidelines for interpreting sequencing variants [22], the variant c.2688del was classified as pathogenic (Table 3).

3.2. Whole-Exome Sequencing. Candidate Mutations in the OTOF Gene. All patients underwent whole-exome sequencing, yielding 12.3 Gbps, 12.0 Gbps, 17.1 Gbps, and 14.2 Gbps of raw data, respectively. More than 99.6% of all raw data was mapped to the human reference genome sequence. The average sequencing depth of the targeted regions was ≥100X, and covered ≥95% of the targeted regions.

We then filtered out variants with an allelic frequency > 0.1% in the gnomAD database and kept variants in the known deafness genes (https://hereditaryhearingloss.org/). Homozygous (c.[2688del];[2688del]) and compound heterozygous damaging variants (i.e., c.[4960G>A];[1469C>G] and c.[2675A>G];[977_2978del]) were found in probands 1-II-2, 2-II-1, and 3-II-4, respectively. All mutations of the OTOF gene were verified in family members by the Sanger sequencing, which showed that their parents were all heterozygous carriers.

3.3. Variation Interpretation

3.3.1. c.2688del in Family 1. The four-year-old proband I-II-2 and his two-year-old sister all carried the c.2688del variant in a homozygous state. They inherited the damaging mutations from both their heterozygous healthy parents. The c.2688del variant is a frameshift mutation causing a loss of function (LOF) of the OTOF gene and LOF is a known mechanism of disease for this gene (PPV1). This novel mutation was absent in 1000 Genomes, ExAC, and gnomAD (PM2). Multiple lines of computational evidence supported a deleterious effect of G nucleotide deletion at position 2688 on the OTOF gene (PP3). The clinical manifestations of the patients were consistent with the phenotype of the disease caused by the OTOF gene (PP4). Thus, based on ACMG standards and guidelines for interpreting sequencing variants [22], the variant c.2688del was classified as pathogenic (Table 3).

3.3.2. Compound Heterozygous Variants c.[4960G>A];[1469C>G] in Family 2. The two-year-old proband 2-II-1, born an artificially inseminated child, was found to carry compound heterozygous variants referred to as c.[4960G>A];[1469C>G]. Of these, c.4960G>A was from the mother, and c.1469C>G was from a sperm donor or occurred de novo. The c.4960G>A is the final base before the splice site, while G-to-A substitution at the position leads to the alteration of the splicing process, which is a known mechanism of disease (PPV1). The minor allelic frequencies of c.4960G>A were very low in 1000 Genomes, ExAC, and gnomAD (PM2), and the mutation was expected to result in aberrant splicing according to prediction softwares (PP3). The clinical manifestations of the patients were consistent with the phenotype of the disease known to be caused by the OTOF gene (PP4). Thus, according to ACMG standards and guidelines, the variants c.4960G>A and c.1469C>G were classified as pathogenic and likely pathogenic, respectively (Table 3).

3.3.3. Compound Heterozygous Variants c.[2675A>G];[2977_2978del] in Family 3. The compound heterozygous variants c.[2675A>G];[2977_2978del] were detected in proband 3-II-4. Among them, the reported mutation of c.2977_2978del was transmitted from the mother and was a frameshift mutation [24]. It causes LOF of the OTOF gene, which is a known mechanism of disease (PPV1). The frequency of mutation c.2977_2978del was very low in 1000 Genomes.
ExAC, and gnomAD (PM2). Multiple prediction softwares support the pathogenicity of this variant (PP3). The patient’s clinical phenotype was highly specific for the OTOF gene (PP4). In addition, the c.2675A>G was from the father, was a missense mutation, and was not found in public population databases, including 1000 Genomes, ExAC, and gnomAD (PM2). There was a mutation in trans of c.2675A>G, which is known to be pathogenic (PM3), and c.2675A>G was expected to yield aberrant splicing according to the prediction softwares (PP3). The patient’s clinical phenotype was highly specific for the OTOF gene (PP4). Thus, the variant c.2977_2978del was classified as pathogenic, and the variant c.2675A>G was categorized as likely pathogenic (Table 3).

4. Discussion

ANSD presents markedly genotypic and phenotypic heterogeneity. However, ANSD explained by mutations in the OTOF gene has been proven to be primarily interrelated with congenital, severe-to-profound, nonsyndromic sensorineural deafness [25]. Herein, our concern with regard to patients affected by congenital deafness, whose clinical and audiological characteristics matched the above phenotype, also met the diagnostic criteria for ANSD (Table 2). Furthermore, bioinformatics analysis confirmed that the three families exhibited two novel mutations (i.e., c.2688del, c.2675A>G) and three reported variations (i.e., c.4960G>A, c.1469C>G) in the OTOF gene.
and c.1469C>G in the OTOF gene [23, 24, 26]. Combining the verification by the Sanger sequencing in the corresponding parents and siblings (Table 3), variants c.[2688del];[2688del], c.[1469C>G];[1469C>G], and c.[2675A>G];[2977_2978del] were confirmed to be likely pathogenic/pathogenic for three families.

Mutations in the OTOF gene, especially those affecting highly conserved domains, display an increased abominable effect on the structure or function of the otoferlin protein. In this study, c.2688del (p.Lys896AsnfsTer104) and c.2977_2978del (p.Gln994ValfsTer7) represented two frameshift mutations. The novel p.Lys896AsnfsTer104 was found in the region between the C2C and C2D domains, while the p.Gln994ValfsTer7 that has been discussed in a familial case of temperature sensitive nonsyndromic auditory neuropathy (TS-NSRAN) was located in the functional domain C2D [24]. Both frameshift mutations (i.e., c.2688del and c.2977_2978del) were predicted to cause the translation process to terminate prematurely, causing the loss of the downstream domain or engendering a truncated otoferlin protein as a consequence. The three identified missense mutations c.4960G>A, c.1469C>G, and c.2675A>G cause transversion of highly conserved amino acids from glycine to serine (p.Gly1654Ser), proline to arginine (p. Pro490Arg), and lysine to arginine (p.Lys892Arg), respectively. Among them, the G>A nucleotide change at position 4960 was located in the exon/intron junction that was expected to result in aberrant splicing, thus causing an abnormal amino acid chain of the otoferlin protein. The reported missense mutation c.1469C>G was located in the relevant C2C domain and was confirmed to affect the function of protein products [23]. The mutation c.2675A>G was found in the region between the C2C and C2D domains and was predicted to result in deleterious splicing. In summary, we speculate that these variations that affect the protein structure or the capacity of proteins to bind Ca^{2+} might cause a reduction or deficiency of neurotransmitters in IHCs synaptic vesicles and the occurrence of the characteristic phenotype of ANSD. However, further studies are warranted to elucidate the specific pathogenic molecular mechanism of these mutations.

Mutations in the OTOF gene cause presynaptic ANSD, with varying prevalence and hotspot mutations in different ethnic cohorts. For example, in Spanish population, the prevalence of nonsyndromic ANSD caused by mutations in the OTOF gene was estimated to be 87%, and the hotspot mutation is c.2485C>T (p.Gln829Ter) [27, 28], while the prevalence is 57% in the Japanese population, and the hotspot mutation is c.5816G>A (p.Arg1939Gln) [29, 30]. Similarly, this frequency was more than 41% in the mainland Chinese population [31], but no hotspot mutations were detected. Despite all of this, clinical management decisions for patients with ANSD lead to cochlear implantation (CI). The effect of CI varies according to the location of the lesion; however, presynaptic ANSD were found suitable for intervention, contrary to postsynaptic ANSD [32]. In this current study, two affected offspring harboring novel homozygous mutations c.2688del in the OTOF gene underwent CI and received acceptable results as expected. Their speech recognition ability was also effectively improved. Hence, prior to this invasive treatment, a precise molecular diagnosis would be helpful in the differential diagnosis and prognosis of patients with ANSD.

5. Conclusions

In conclusion, we confirmed that four individuals with ANSD (i.e., 1-II-2, 1-II-3, 2-III-1, and 3-II-4) had mutations in the OTOF gene as shown by next-generation sequencing. The proband 1-II-2 and his sister 1-II-3 carried a homozygous variants c.[2688del];[2688del]. The compound heterozygous variants defined as c.[4960G>A];[1469C>G] and c.[2675A>G];[2977_2978del] were identified in probands 2-II-1 and 3-II-4, respectively. Convincing evidence supports the notion that these variations are causative factors of nonsyndromic ANSD in the three families. The discovery of c.2688del and c.2675A>G mutations expands the spectrum of mutations found in the OTOF gene and provides a new reference point for the genetic diagnosis of auditory neuropathy.

Data Availability

The data that support the findings of this study are available from the corresponding authors upon reasonable request.

Conflicts of Interest

The authors declare no conflict of interest.

Authors’ Contributions

Wei Lu and Bei Chen performed genetic counseling. Wenxue Tang designed study. Rongqun Zhai, Haifeng Feng, and Hongen Xu performed the original draft preparation, data analysis, and revision of the manuscript. Huanei Liu, Ruijun Li, Yongan Tian, and Danhua Liu performed the whole-exome sequencing, Sanger sequencing, and variant interpretation. Qingli Li and Bin Zuo are responsible for information collection and phenotypic analysis. All authors have read and approved the final manuscript. Rongqun Zhai and Haifeng Feng contributed equally to this work.

Acknowledgments

The study was funded by the Youth Foundation of the First Affiliated Hospital of Zhengzhou University (Grant no. 70158) and the Scientific and Technological Research in Henan Province, China (Grant no. 192102310383). We sincerely thank all patients and their families for participation and cooperation in this study. The data analysis was supported by the Supercomputing Center in Zhengzhou University (Zhengzhou).

References

[1] A. Pandy, "Genetic hearing loss: the journey of discovery to destination - how close are we to therapy?," Molecular Genetics & Genomic Medicine, vol. 4, no. 6, pp. 583–587, 2016.
[2] A. Starr, T. W. Picton, Y. Sininger, L. J. Hood, and C. I. Berlin, "Auditory neuropathy," Brain, vol. 119, no. 3, pp. 741–753, 1996.

[3] A. Starr, "Auditory neuropathy and inner hair cell and synapses," Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, vol. 43, no. 5, pp. 323–326, 2008.

[4] A. Starr, Y. S. Sininger, and H. Pratt, "The varieties of auditory neuropathy," Journal of Basic & Clinical Physiology & Pharmacology, vol. 11, no. 3, pp. 215–230, 2000.

[5] B. Cone-Wesson, B. R. Vohr, Y. S. Sininger et al., "Identification of neonatal hearing impairment: infants with hearing loss," Ear and Hearing, vol. 21, no. 5, pp. 488–507, 2000.

[6] V. K. Manchaiah, F. Zhao, A. A. Danesh, and R. Duprey, "The genetic basis of auditory neuropathy spectrum disorder (ANSD)," International Journal of Pediatric Otorhinolaryngology, vol. 75, no. 2, pp. 151–158, 2011.

[7] F. J. Del Castillo and I. Del Castillo, "Genetics of isolated auditory neuropathies," Frontiers in bioscience, vol. 17, no. 1, pp. 1251–1265, 2012.

[8] S. Yasunaga, M. Grati, M. Cohen-Salmon et al., "A mutation in OTOF, encoding otoferlin, a FER-1-like protein, causes DFNB9, a nonsyndromic form of deafness," Nature Genetics, vol. 21, no. 4, pp. 363–369, 1999.

[9] S. Yasunaga, M. Grati, S. Chardenoux et al., "OTOF Encodes Multiple Long and Short Isoforms: Genetic Evidence That the Long Ones Underlie Recessive Deafness DFNB9," American Journal of Human Genetics, vol. 67, no. 3, pp. 591–600, 2000.

[10] I. Roux, S. Safieddine, R. Nouvian et al., "Otoferlin, defective in a human deafness form, is essential for exocytosis at the auditory ribbon synapse," Cell, vol. 127, no. 2, pp. 277–289, 2006.

[11] H. Takago, T. Oshima-Takago, and T. Moser, "Disruption of otoferlin alters the mode of exocytosis at the mouse inner hair cell ribbon synapse," Frontiers in Molecular Neuroscience, vol. 11, 2018.

[12] N. Michalski, J. D. Goutman, S. M. Auclair et al., "Otoferlin acts as a Ca2+ sensor for vesicle fusion and vesicle pool replenishment at auditory hair cell ribbon synapses," eLife, vol. 6, 2017.

[13] M. Tertrais, Y. Bouleau, A. Empoto et al., "Viral transfer of mini-otoferlins partially restores the fast component of exocytosis and uncovers ultrafast endocytosis in auditory hair cells of otoferlin knock-out mice," The Journal of neuroscience : the official journal of the Society for Neuroscience, vol. 39, no. 18, pp. 3394–3411, 2019.

[14] G. Zanazzi and G. Matthews, "The molecular architecture of ribbon presynaptic terminals," Molecular Neurobiology, vol. 39, no. 2, pp. 130–148, 2009.

[15] I. Rouillon, A. Marcola, I. Roux et al., "Results of cochlear implantation in two children with mutations in the OTOF gene," International Journal of Pediatric Otorhinolaryngology, vol. 70, no. 4, pp. 689–696, 2006.

[16] R. Varga, P. M. Kelley, B. J. Keats et al., "Non-syndromic recessive auditory neuropathy is the result of mutations in the otoferlin (OTOF) gene," Journal of Medical Genetics, vol. 40, no. 1, pp. 45–50, 2003.

[17] M. Rodríguez-Ballesteros, F. J. del Castillo, Y. Martín et al., "Auditory neuropathy in patients carrying mutations in the otoferlin gene (OTOF)," Human Mutation, vol. 22, no. 6, pp. 451–456, 2003.

[18] Z. Pan, H. Xu, Y. Tian et al., "Perrault syndrome: clinical report and retrospective analysis," Molecular Genetics & Genomic Medicine, vol. 8, no. 10, p. e1445, 2020.

[19] A. M. Bolger, M. Lohse, and B. Usadel, "Trimomatic: a flexible trimmer for Illumina sequence data," Bioinformatics, vol. 30, no. 15, pp. 2114–2120, 2014.

[20] H. Li, "Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM," 2013, http://arxiv.org/abs/1303.3997.

[21] A. McKenna, M. Hanna, E. Banks et al., "The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data," Genome Research, vol. 20, no. 9, pp. 1297–1303, 2010.

[22] S. Richards, N. Aziz, S. Bale et al., "Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology," Genetics in Medicine, vol. 17, no. 5, pp. 405–423, 2015.

[23] N. M. Al-Wardy, M. N. Al-Kindi, M. J. Al-Khbouri, Y. Tamimi, and G. Van Camp, "A novel missense mutation in the C2C domain of otoferlin causes profound hearing impairment in an Omani family with auditory neuropathy," Saudi Medical Journal, vol. 37, no. 10, pp. 1068–1075, 2016.

[24] D. Y. Wang, Y. C. Wang, D. Weil et al., "Screening mutations of OTOFgene in Chinese patients with auditory neuropathy, including a familial case of temperature-sensitive auditory neuropathy," BMC Medical Genetics, vol. 11, no. 1, 2010.

[25] Y. I. Iwasa, S. Y. Nishio, A. Sugaya et al., "OTOF mutation analysis with massively parallel DNA sequencing in 2,265 Japanese sensorineural hearing loss patients," PLoS One, vol. 14, no. 5, 2019.

[26] J. Romanos, L. Kimura, F. Zhao et al., "Novel OTOF mutations in Brazilian patients with auditory neuropathy," Journal of Human Genetics, vol. 54, no. 7, pp. 382–385, 2009.

[27] M. Rodríguez-Ballesteros, R. Reynoso, M. Olarte et al., "A multicenter study on the prevalence and spectrum of mutations in the otoferlin gene (OTOF) in subjects with nonsyndromic hearing impairment and auditory neuropathy," Human Mutation, vol. 29, no. 6, pp. 823–831, 2008.

[28] V. Migliosi, S. Modamio-Højbjørn, M. A. Moreno-Pelayo et al., "Q829X, a novel mutation in the gene encoding otoferlin (OTOF), is frequently found in Spanish patients with prelingual non-syndromic hearing loss," Journal of Medical Genetics, vol. 39, no. 7, pp. 502–506, 2002.

[29] T. Matsunaga, H. Mutai, S. Kunishima et al., "A prevalent founder mutation and genotype-phenotype correlations of OTOF in Japanese patients with auditory neuropathy," Clinical Genetics, vol. 82, no. 5, pp. 425–432, 2012.

[30] Y. I. Iwasa, S. Y. Nishio, H. Yoshimura, Y. Kanda, and S. I. Usami, "OTOF mutation screening in Japanese severe to profound recessive hearing loss patients," BMC Medical Genetics, vol. 14, no. 1, p. 95, 2013.

[31] Q. J. Zhang, B. Han, L. Lan et al., "High frequency of OTOF mutations in Chinese infants with congenital auditory neuropathy spectrum disorder," Clinical Genetics, vol. 90, no. 3, pp. 238–246, 2016.

[32] W. P. Gibson and J. M. Graham, "Editorial: ‘auditory neuropathy’ and cochlear implantation - myths and facts," Cochlear Implants International, vol. 9, no. 1, pp. 1–7, 2008.